Featured Story | By Kyle LaHucik Centessa Pharmaceuticals' hemophilia drug reduced bleeding rates and spontaneous joint bleeds in a midstage study, setting the biotech up to move the candidate closer to regulatory submission. read more |
| |
|---|
|
Top Stories By Kyle LaHucik Gene therapy biotech Orchard Therapeutics has picked a shiny apple from Novartis, bringing Nicoletta Loggia, Ph.D. on as chief technical officer after a 17-year career at the Swiss pharma. Loggia previously served as global head of cell and gene therapies for Novartis—a high profile part of the pharma's business that in recent years has launched Zolgensma. read more By Annalee Armstrong Amgen has already won the KRAS race by getting Lumakras across the finish line, but Cardiff Oncology has just rolled out some early data for a follow-on candidate showing partial responses and extended survival without disease progression compared to standard of care. read more By Nick Paul Taylor The FDA has become the latest organization to validate the potential of Vor Biopharma’s approach to CRISPR-powered cell engineering, granting fast-track status to its lead asset shortly after Johnson & Johnson struck a deal to access the technology. read more By Nick Paul Taylor Cells derived from bone marrow have shown some promise in the treatment of patients with badly blocked arteries over the past 20 years without ever landing a knockout blow on the condition. Now, Ixaka has edged closer to showing if its prospect REX-001 can buck the trend by coming through an interim data analysis. read more By Angus Liu A team led by scientists at the Broad Institute has developed adeno-associated viruses as gene therapy vectors. The vehicles can target muscle tissue, and therapies based them are effective in animals at low doses, potentially reducing the risk of liver damage, they said. read more By Andrea Park Boehringer Ingelheim will look to Twist’s “Library of Libraries” of antibody sequences to single out potential treatments for drug targets. read more By Noah Higgins-Dunn Apellis Pharmaceuticals’ pegcetacoplan posted mixed results in two late-stage trials studying the C3 inhibitor in patients living with geographic atrophy (GA). Despite the mixed showing, CEO Cedric Francois thinks the med's performance was strong enough to warrant an FDA nod. read more By Eric Sagonowsky Before Biogen scored an FDA approval for Alzheimer's drug aducanumab, the company probably hoped its launch would go much smoother than the last three months have been. It turns out Biogen's CEO Michel Vounatsos is willing to say so publicly. read more By Angus Liu A court says AbbVie can't force Takeda to fulfill Lupron supply obligations. Takeda will make 150 million doses of Novavax's COVID-19 vaccine for Japan. A joint venture between Juno Therapeutics and WuXi AppTec won China approval for a Breyanzi sister CAR-T therapy. And more. read more By Kyle LaHucik Former FDA Commissioner Stephen Hahn is joining YourBio Health as interim chief medical officer. Gilead's global head of liver diseases, Tram Tran, M.D., will be Glympse Bio's first chief medical officer. And Orchard Therapeutics picks an apple from Novartis' field, snagging cell and gene therapies leader Nicoletta Loggia, Ph.D., as chief technical officer. read more Resources Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: XIFIN inc. Download the Value of Precision Medicine Informatics (PMI) Initiatives report to learn about the technology, data types, and the value derived from more than 100 PMI initiatives. Sponsored by: EVERSANA Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how. Sponsored by: Thermo Fisher Scientific Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications. Sponsored by: Cascade Chemistry by Aceto Read four customer success stories and four success factors that helped move pharmaceutical customers of Cascade Chemistry by Aceto quickly and effectively to clinic with trial-ready APIs. Sponsored by: ConnectiveRx Topple barriers to getting patients started on therapy. Guide them with mobile. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
